KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) Equity Ratio (2020 - 2026)

AbCellera Biologics filings provide 7 years of Equity Ratio readings, the most recent being 0.72 for Q1 2026.

  • Quarterly Equity Ratio fell 5.7% to 0.72 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.72 through Mar 2026, down 5.7% year-over-year, with the annual reading at 0.71 for FY2025, 8.2% down from the prior year.
  • Equity Ratio hit 0.72 in Q1 2026 for AbCellera Biologics, up from 0.71 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.81 in Q1 2023 and bottomed at 0.71 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.76, with a median of 0.77 recorded in 2024.
  • The largest annual shift saw Equity Ratio fell 10.59% in 2022 before it rose 6.39% in 2023.
  • AbCellera Biologics' Equity Ratio stood at 0.8 in 2022, then decreased by 3.25% to 0.77 in 2023, then grew by 0.24% to 0.78 in 2024, then dropped by 8.2% to 0.71 in 2025, then grew by 0.72% to 0.72 in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Equity Ratio are 0.72 (Q1 2026), 0.71 (Q4 2025), and 0.71 (Q3 2025).